Neurocrine Biosciences (NBIX) is rallying after its first-quarter 2026 earnings report showed a sizable beat versus consensus expectations, powered by commercial execution and sales momentum in its core franchise. The company’s results and outlook reduced near-term uncertainty around demand and profitability, prompting fresh buying interest in the shares. (sec.gov)

For Q1 2026, Neurocrine reported total revenues of $814.5 million versus $572.6 million a year earlier, and INGREZZA first-quarter net product sales of $656.9 million, up 20% year over year. On a non-GAAP basis, net income was $200.5 million and EPS was $1.94, up from $71.5 million and $0.70 in the prior-year quarter. (sec.gov)

Management reiterated full-year 2026 INGREZZA net product sales guidance of $2.7 billion to $2.8 billion, signaling confidence that recent prescription trends and patient demand can be sustained through the remainder of the year. With INGREZZA remaining the company’s dominant revenue driver, maintaining guidance alongside a strong quarter is being treated as a constructive read-through for 2026 cash generation. (sec.gov)

Following the print, at least one major firm raised its price target while keeping a bullish rating, reflecting model updates driven by the quarter’s results and reinforced confidence in the near-term earnings trajectory. That type of post-earnings recalibration often amplifies upside moves when positioning into the report is cautious. (investing.com)